Skip to main content
Erschienen in: Clinical and Translational Oncology 12/2020

23.05.2020 | Research Article

Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer

verfasst von: Y. Zhao, N. Yang, X. Wang, Y. Huang, X. Zhou, D. Zhang

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Patients presenting with lymphovascular space invasion (LVSI) had an absolute decrease in survival. In our present study, the potential roles of LVSI on tumor characteristics was explored to predict the difference in the prognosis of ER and HER2 positive T1 tumors.

Methods

A total of 142 breast cancer patients diagnosed with ER+ and HER2+ tumors whose tumor size was ≤ 2 cm were included in this analysis. One hundred forty-two patients were divided into four groups, group 1 (lymph nodes+ and LVSI+), group 2 (lymph nodes+ and LVSI−), group 3 (lymph nodes− and LVSI+), group 4 (lymph nodes− and LVSI−). Univariate and multivariate Cox proportional hazard models were used to identify independent prognostic factors and calculate the HR and 95% CI. Kaplan–Meier and Cox regression models were used to test the prognostic significance.

Results

LVSI positivity was significantly associated with patient age, menopausal status, tumor size, lymph node status, Ki67, PR, and tumor grade. In the univariate and multivariate model, LVSI, PR, and Ki67 were significantly associated with DFS, and LVSI, lymph node status, PR, and Ki67 were significantly associated with OS. LVSI was significantly related to increased risk of DFS and OS only in the PR-negative and low-positive subgroups. It was a prognostic factor for DFS but not for OS in women with low Ki67 and was associated with DFS and OS in high-Ki67 tumors. Furthermore, patients who presented with only LVSI had a significantly worse survival rate than those with lymph node metastasis without LVSI in small tumors.

Conclusion

The presence of LVSI was highlighted as a variable significant to survival. In further clinical practice, patients with LVSI may need more intensive treatment in certain populations.
Literatur
1.
Zurück zum Zitat Alvarez Goyanes RI, Escobar Perez X, Camacho Rodriguez R, et al. Hormone receptors and other prognostic factors in breast cancer in Cuba. MEDICC Rev. 2010;12(1):36–40.PubMed Alvarez Goyanes RI, Escobar Perez X, Camacho Rodriguez R, et al. Hormone receptors and other prognostic factors in breast cancer in Cuba. MEDICC Rev. 2010;12(1):36–40.PubMed
2.
Zurück zum Zitat Saurel CA, Patel TA, Perez EA. Changes to adjuvant systemic therapy in breast cancer: a decade in review. Clin Breast Cancer. 2010;10(3):196–208.PubMed Saurel CA, Patel TA, Perez EA. Changes to adjuvant systemic therapy in breast cancer: a decade in review. Clin Breast Cancer. 2010;10(3):196–208.PubMed
3.
Zurück zum Zitat Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.PubMed Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.PubMed
4.
Zurück zum Zitat Sawe RT, Kerper M, Badve S, et al. Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration. BMC Cancer. 2016;16:204.PubMedPubMedCentral Sawe RT, Kerper M, Badve S, et al. Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration. BMC Cancer. 2016;16:204.PubMedPubMedCentral
5.
Zurück zum Zitat Mohammed RA, Martin SG, Mahmmod AM, et al. Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. J Pathol. 2011;223:358–65.PubMed Mohammed RA, Martin SG, Mahmmod AM, et al. Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. J Pathol. 2011;223:358–65.PubMed
6.
Zurück zum Zitat Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Panel Members: Tailoring therapies—improving the management of early breast cancer: St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;8:1533–46. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Panel Members: Tailoring therapies—improving the management of early breast cancer: St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;8:1533–46.
7.
Zurück zum Zitat André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28:1700–12.PubMedPubMedCentral André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28:1700–12.PubMedPubMedCentral
8.
Zurück zum Zitat Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97:1254–61.PubMed Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97:1254–61.PubMed
9.
Zurück zum Zitat Shen SD, Xiao GF, Du RC, et al. Predictors of lymphovascular invasion identified from pathological factors in Chinese patients with breast cancer. Oncotarget. 2018;9(2):2468–74.PubMed Shen SD, Xiao GF, Du RC, et al. Predictors of lymphovascular invasion identified from pathological factors in Chinese patients with breast cancer. Oncotarget. 2018;9(2):2468–74.PubMed
10.
Zurück zum Zitat Sayed S, Moloo Z, Wasike R, Bird P, Oigara R, Govender D, Kibera J, Carrara H, Saleh M. Is breast cancer from sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya. Breast. 2014;23(5):591–6.PubMed Sayed S, Moloo Z, Wasike R, Bird P, Oigara R, Govender D, Kibera J, Carrara H, Saleh M. Is breast cancer from sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya. Breast. 2014;23(5):591–6.PubMed
11.
Zurück zum Zitat Ignatov T, Eggemann H, Burger E, Costa SD, Ignatov A. Management of small T1a/b breast cancer by tumor subtype. Breast Cancer Res Treat. 2017;163(1):111–8.PubMed Ignatov T, Eggemann H, Burger E, Costa SD, Ignatov A. Management of small T1a/b breast cancer by tumor subtype. Breast Cancer Res Treat. 2017;163(1):111–8.PubMed
12.
Zurück zum Zitat Vaz-Luis I, Ottesen RA, Hughes ME, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014;32(20):2142–50.PubMedPubMedCentral Vaz-Luis I, Ottesen RA, Hughes ME, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014;32(20):2142–50.PubMedPubMedCentral
13.
Zurück zum Zitat Hammond ME, Hayes DF, Dowestt M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–e72.PubMed Hammond ME, Hayes DF, Dowestt M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–e72.PubMed
14.
Zurück zum Zitat Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323–33.PubMed Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323–33.PubMed
15.
Zurück zum Zitat Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.PubMedPubMedCentral Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.PubMedPubMedCentral
16.
Zurück zum Zitat Rosen PP. Tumor emboli in intramammary lymphatics in breast carcinoma: pathologic criteria for diagnosis and clinical significance. Pathol Annu. 1983;18:215–32.PubMed Rosen PP. Tumor emboli in intramammary lymphatics in breast carcinoma: pathologic criteria for diagnosis and clinical significance. Pathol Annu. 1983;18:215–32.PubMed
17.
Zurück zum Zitat Hoda Syed A, Hoda Rana S, Scott M, et al. Issues relating to lymphovascular invasion in breast cancer. Adv Anat Pathol. 2006;13:308–15.PubMed Hoda Syed A, Hoda Rana S, Scott M, et al. Issues relating to lymphovascular invasion in breast cancer. Adv Anat Pathol. 2006;13:308–15.PubMed
18.
Zurück zum Zitat Bauer K, Parise C, Caggiano V. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer. 2010;10:228.PubMedPubMedCentral Bauer K, Parise C, Caggiano V. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer. 2010;10:228.PubMedPubMedCentral
19.
Zurück zum Zitat Ugras S, Stempel M, Patil S, Morrow M. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. Ann Surg Oncol. 2014;21:3780–6.PubMedPubMedCentral Ugras S, Stempel M, Patil S, Morrow M. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. Ann Surg Oncol. 2014;21:3780–6.PubMedPubMedCentral
20.
Zurück zum Zitat Sara MT, William TB, Hao G, et al. Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). J Clin Oncol. 2017;35(15):511. Sara MT, William TB, Hao G, et al. Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). J Clin Oncol. 2017;35(15):511.
21.
Zurück zum Zitat Colleoni M, Rotmensz N, Maisonneuve P, et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol. 2007;18:1632–40.PubMed Colleoni M, Rotmensz N, Maisonneuve P, et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol. 2007;18:1632–40.PubMed
22.
Zurück zum Zitat Zhao Y, Zhang DW. Biomarker alteration to neoadjuvant chemotherapy predict pathological response and prognosis in breast cancer patients. Cancer Genet Epigenet. 2018;6(1):1–12. Zhao Y, Zhang DW. Biomarker alteration to neoadjuvant chemotherapy predict pathological response and prognosis in breast cancer patients. Cancer Genet Epigenet. 2018;6(1):1–12.
23.
Zurück zum Zitat Prat A, Cheang MC, Martín M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;31(2):203–9.PubMed Prat A, Cheang MC, Martín M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;31(2):203–9.PubMed
24.
Zurück zum Zitat Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83.PubMed Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83.PubMed
25.
Zurück zum Zitat Elkablawy MA, Albasri AM, Mohammed RA, Hussainy AS, Nouh MM, Alhujaily AS. Ki67 expression in breast cancer correlation with prognostic markers and clinicopathological parameters in Saudi patients. Saudi Med J. 2016;37:137–41.PubMedPubMedCentral Elkablawy MA, Albasri AM, Mohammed RA, Hussainy AS, Nouh MM, Alhujaily AS. Ki67 expression in breast cancer correlation with prognostic markers and clinicopathological parameters in Saudi patients. Saudi Med J. 2016;37:137–41.PubMedPubMedCentral
26.
Zurück zum Zitat Milam MR, Frumovitz M, dos Reis R, et al. Preoperative lymph-vascular space invasion is associated with nodal metastases in women with early-stage cervical cancer. Gynecol Oncol. 2007;106:12–5.PubMed Milam MR, Frumovitz M, dos Reis R, et al. Preoperative lymph-vascular space invasion is associated with nodal metastases in women with early-stage cervical cancer. Gynecol Oncol. 2007;106:12–5.PubMed
27.
Zurück zum Zitat Ferrandina G, Pedone Anchora L, Gallotta V, et al. Can we define the risk of lymph node metastasis in early-stage cervical cancer patients? A large-scale, retrospective study. Ann Surg Oncol. 2017;24:2311–8.PubMed Ferrandina G, Pedone Anchora L, Gallotta V, et al. Can we define the risk of lymph node metastasis in early-stage cervical cancer patients? A large-scale, retrospective study. Ann Surg Oncol. 2017;24:2311–8.PubMed
Metadaten
Titel
Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer
verfasst von
Y. Zhao
N. Yang
X. Wang
Y. Huang
X. Zhou
D. Zhang
Publikationsdatum
23.05.2020
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 12/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02369-9

Weitere Artikel der Ausgabe 12/2020

Clinical and Translational Oncology 12/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.